Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by subaru1ion Aug 30, 2023 2:40pm
104 Views
Post# 35612500

RE:Breaking News

RE:Breaking NewsI guess Pfizer has a little weight at the White House and to bring forth a new class of cannabinoid based drugs.  Biden selected 10 drugs yesterday to renegotiate pricing to reduce government spending costs on Medicare.   Pfizer also some has some revenue coming their way with the build up of the 'trippledemic'....COVID, Influenza, RSV.    Plenty of pocket change to finally make their move with LABS.   

Considering the NIH (U.S. Federal) is funding cannbinoid based clinical trials and the DEA allowed the importation of THC containing API's from LABS, the news of descheduling was only a matter of time.  

Like Bourla said, 1 in 3 will be affected by cancer in their life times.  Pfizer, City of Hope Duarte California and cannabinoid based API's.  

Peace and tranquility. 
<< Previous
Bullboard Posts
Next >>